2022-RA-1232-ESGO Key aspects of fertility preservation in cancer patients. (20th October 2022)

• Record Type: Journal Article
• Authors: Lavrinovich, Olga; Yakovleva, Maria; Smirnova, Olga; Urmancheeva, Adel; Berlev, Igor
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A178
• Page End: A179
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.382
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Fertility-preserving treatment of malignant tumors and improving survival rates after recovery, explained the introduction of fertility preservation methods into the daily oncological practice. Methodology: Depending on the oncological pathology the following assisted reproductive technologies (ART) were used: conservative surgery of the reproductive organs in the early stages of disease, ovarian stimulation followed by cryopreservation techniques (of embryos, oocytes, ovarian cortex and semen), interoperation collecting of the ovarian cortex for the oocyte in-vitro maturation (OTO-IVM).The exclusion criteria were a high extension of the oncological process, poor oncological prognosis, menopausal ovarian reserve. Results: Since March 2021 in N.N. Petrov NMRC of oncology in were consulted 370 primary patients: 314 women (85%) and 56 men (15%). The oncological disease's distribution was as follows: 31% (115 patients) reproductive system malignant tumors, 26% (96 patients) breast tumors, 15% (55 patients) with hemoblastoses, 10.2% (38 patients) bone and soft tissue tumors, 8.7% (32 patients) with germ cell tumors, 9.1% (34 patients) with tumors of other localizations, including brain tumors. The mean age of the consulted patients was 28.4 years (19 to 42 years). As part of the delayed motherhood program 60 ovarian stimulations followed by cryopreservation of oocytes and embryos were performed, 6 intraoperative collecting of the ovarian cortex for OTO-IVM were performed (in 3 cases oocytes cryopreservation was successful). More than 40 men were sent for semen cryopreservation, which is 71% of all consulted male patients. Conclusion: The integration of fertility preservation technologies into the treatment of oncological patients demonstrates a high demand both among oncological patients and clinicians. An important aspect is the understanding that the leading role in the fertility preservation of oncological patients belongs to the oncological concilium, which must be carried out in a multidisciplinary way in specialised centers only.